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Objectives This analysis from the LUNAR (Limiting UNdertreatment of lipids in ACS with Rosuvastatin) study assessed lipid
changes 1 to 4 days after onset of acute coronary syndromes (ACS), before initiation of study treatment.
Background Early studies indicated that cholesterol levels decrease significantly after ACS. However, most studies were small
or did not measure low-density lipoprotein cholesterol (LDL-C) directly, and many used nonfasting or retrospec-
tive data. More recent studies suggest less pronounced changes in cholesterol levels after ACS.
Methods The LUNAR trial is a prospective, multicenter, randomized, open-label study in adults hospitalized for acute
ST-segment elevation myocardial infarction (STEMI), non-STEMI, or unstable angina (UA). Blood samples were
taken at median times after onset of ACS symptoms of 26 h (Day 1, fasting or nonfasting sample), 43 h (Day 2,
fasting sample), and 84 h (Day 4, fasting sample) for direct measurement of serum lipid levels before study
treatments were started.
Results Of 507 patients available for analysis, 212 were admitted for STEMI, 176 for non-STEMI, and 119 for UA. The
LDL-C levels decreased in the 24 h after admission (from 136.2 to 133.5 mg/dl), followed by an increase over
the subsequent 2 days (to 141.8 mg/dl). These changes did not seem to be clinically meaningful. Similar
changes were observed for total cholesterol and smaller changes for high-density lipoprotein cholesterol; fasting
triglyceride levels did not change.
Conclusions Mean lipid levels vary relatively little in the 4 days after an ACS and can be used to guide selection of lipid-
lowering medication. (LUNAR Phase IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute
Coronary Syndromes; NCT00214630) (J Am Coll Cardiol 2008;51:1440–5) © 2008 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.11.075t
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hncreasing evidence suggests that statins decrease morbidity
nd mortality when administered early after admission to
atients with an acute coronary syndrome (ACS) (1–4).
lthough current guidelines recommend measurement of
erum lipids after admission for patients with an ACS (5,6),
ess than one-half of these patients have serum lipids
easured within 24 h of admission. This is of importance
ecause in-hospital lipid testing and initiation of statin use
n patients with an ACS are strongly associated with their
se on discharge (7,8).
Many physicians fail to measure serum lipids early after
dmission for an ACS in part because of their understanding
rom the *Department of Internal Medicine, University of Michigan School of
edicine, Ann Arbor, Michigan; †Department of Cardiology, Brigham and
omen’s Hospital, Harvard Medical School, Boston, Massachusetts; and ‡Astra-
eneca LP, Wilmington, Delaware. The LUNAR study and the current analysis were
upported and funded by AstraZeneca LP. Dr Pitt has served as a consultant to
straZeneca, Novartis, and Pfizer. Drs Ycˇas and Raichlen are employed by Astra-
eneca LP. A preliminary version of this analysis was presented as a poster at the 55th
nnual Scientific Session of the American College of Cardiology, Atlanta, Georgia,
arch 11 to 14, 2006.m
Manuscript received August 24, 2007; revised manuscript received November 1,
007, accepted November 14, 2007.hat such measurements are unreliable because of an early
ecrease in serum total cholesterol (TC) and low-density
ipoprotein cholesterol (LDL-C) after ACS. As early as 1971,
yfe et al. (9) noted apparent decreases in TC during hospi-
alization of patients with an ACS. Since then, a wide range of
lterations in serum lipids has been reported associated with
ospitalization for an ACS. For example, Sniderman and Teng
10) found that LDL-C decreased by 18% to 53% in 6 patients
ith myocardial infarction (MI) between Day 1 and Days 7 to
, but LDL-C increased by 13% to 32% in 3 other patients.
See page 1446
osenson (11) cited a general consensus among many studies
upporting a large decline in lipid and lipoprotein levels and
ostulated multiple causes that included an increase in serum
riglycerides (TG), changes associated with an acute-phase
eaction, and changes in the fasting state. According to this
iew, reliable measurement of serum lipids might not be
chieved until 1 to 2 months after discharge. These earlier data,
owever, were derived from relatively small populations, and in
ost circumstances, LDL-C was indirectly determined by
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April 15, 2008:1440–5 Lipid Levels After ACSalculation based on lipid levels measured from samples taken
n varying states of fasting and hydration. Baseline lipid values
ere often imputed from late post-discharge samples.
Accurate knowledge of baseline lipid levels may affect the
nitiation of lipid-lowering therapy, the selection of a
pecific statin and its dosage, and recognition of the poten-
ial need for adjunctive lipid therapy, and may influence the
atient’s willingness to adhere to a recommendation for
ong-term lipid-lowering therapy.
The LUNAR (Limiting UNdertreatment of lipids in
CS with Rosuvastatin) trial is a prospective, multicenter
tudy in which patients hospitalized for an ACS without
tatin treatment have a measurement of serum lipids on
ays 1, 2, and 4 after the onset of the event, with both
irect and indirect measurement of LDL-C. Thus, the
UNAR study provides an opportunity to prospectively
xamine the changes in serum lipid parameters in a rela-
ively large trial under contemporary conditions.
ethods
atient selection. Patients 18 to 75 years of age who were
ot on lipid-lowering therapy for at least the preceding 4
eeks were eligible for screening on admission to the
ospital within 48 h of onset of ischemic symptoms. Patients
ould participate if they had unstable angina (UA) or an
cute non–ST-segment elevation myocardial infarction
non-STEMI); those with an acute STEMI were eligible if
hey had undergone successful reperfusion with a thrombo-
ytic agent or primary catheter-based intervention within
2 h of symptom onset. Female patients could not be
regnant and were required to be sterile or using effective
ontraception to participate in the study.
Patients were excluded for any of the following reasons:
ncontrolled diabetes or hypothyroidism; acute liver disease or
epatic dysfunction; elevation of serum creatine kinase not due
o myocardial injury; serum creatinine2.0 mg/dl; pulmonary
dema; moderate or severe congestive heart failure; ventricular
brillation or sustained ventricular tachycardia; prior Q-wave
nfarct, stroke, sepsis, acute pericarditis, systemic or pulmonary
mbolus, severe anemia (hematocrit28%), or participation in
nother investigational drug study within the previous 4 weeks;
oronary artery bypass graft surgery within the past 3 months;
r previous percutaneous coronary intervention within the past
months.
Each site obtained approval of the study protocol from an
nstitutional review board or an independent ethics com-
ittee; all patients provided signed informed consent. The
tudy was conducted in accordance with the ethical princi-
les of the Declaration of Helsinki.
he LUNAR study design. The LUNAR study is a pro-
pective, multicenter, randomized, open-label, 3-arm,
arallel-group, 12-week study begun in September 2003
AstraZeneca study D3560L00021 [4522US/0001]). The
rimary objective of the LUNAR study is to compare the
fficacy of rosuvastatin 20 and 40 mg with that of atorva-
A
utatin 80 mg in lowering levels of
DL-C over 6 to 12 weeks of
nce-daily therapy. Study investi-
ators are blinded to the results of
nd-point assessments.
retreatment lipid assessments.
lood samples were drawn on
dmission to the hospital (Day 1,
asting or nonfasting sample), af-
er fasting at least 12 h overnight
Day 2), and before randomiza-
ion to study treatment (Day 4,
asting sample). The date and
ime of onset of ACS symptoms
nd of the first blood sample
ere recorded. Serum levels of
DL-C were measured with the
irect LDL-C Plus process (Roche Diagnostics, Indianap-
lis, Indiana) at a central facility (Medical Research Labo-
atories, Highland Heights, Kentucky). Serum levels of
igh-density lipoprotein cholesterol (HDL-C), TC, and
G were also measured. The LDL-C was calculated indi-
ectly by the Friedewald equation (12) for samples obtained
nder fasting conditions and for which TG levels were
400 mg/dl. Values for LDL-C obtained by direct mea-
urement correlated well with those calculated indirectly by
he Friedewald equation (r  0.97, slope  1.0; data from
ay 2), with calculated LDL-C levels averaging 11.3 mg/dl
ower than directly measured LDL-C levels. Only patients
ith measurements at all 3 time points were included in this
nalysis.
oncomitant medications. Patients must not have used
ipid-lowering medication within the previous 4 weeks.
ipid-regulating drugs and enzyme inducers, such as phe-
ytoin, phenobarbital, and carbamazepine, were prohibited
o prevent confounding effects on study assessments. Med-
cations were disallowed if they increased the risk of
yopathy or caused other safety concerns when coadmin-
stered with study medications.
tatistical analysis. Baseline values for LDL-C, HDL-C,
nd TC were obtained on Day 1 (fasting or nonfasting). For
G, only fasting measurements were included in the anal-
sis. Data were summarized as means with standard devia-
ions. Analysis of variance was used to examine within-
atient Demographic Characteristics
Table 1 Patient Demographic Characteristics
All ACS
(n  507)
STEMI
(n  212)
Non-STEMI
(n  176)
UA
(n  119)
Gender, n (%)
Male 399 (78.7) 169 (79.2) 142 (80.7) 88 (74.0)
Female 108 (21.3) 43 (20.3) 34 (19.3) 31 (26.0)
Age, yrs
Mean (SD) 53.4 (9.0) 53.4 (8.9) 52.9 (8.5) 54.4 (9.8)
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
HDL-C  high-density
lipoprotein cholesterol
IQR  interquartile range
LDL-C  low-density
lipoprotein cholesterol
STEMI  ST-segment
elevation myocardial
infarction
TC  total cholesterol
TG  triglyceride(s)
UA  unstable anginaCS  acute coronary syndromes; STEMI  ST-segment
nstable angina.elevation myocardial infarction; UA 
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Lipid Levels After ACS April 15, 2008:1440–5atient differences between various time points. To assess
airwise differences between time point observations, the
cheffé adjustment for multiple comparisons was applied.
tatistical significance was defined as p  0.05. Changes in
ipid values were defined as the signed difference between
he later and earlier time points, with a negative value
ndicating a decrease.
esults
atients. Of the 828 patients randomized in the LUNAR
rial, 507 patients had direct LDL-C measurements at all 3
ime points needed for the present analysis. Demographic
haracteristics of the analysis population are summarized in
able 1. Blood sampling was performed at median times
fter onset of ACS symptoms of 26 h (Day 1), 43 h (Day 2),
nd 84 h (Day 4).
holesterol levels. Mean LDL-C, HDL-C, and TC lev-
ls are shown in Figure 1. These lipid levels seemed to
ecrease slightly from Day 1 to Day 2 and to increase again
y Day 4 (Table 2). These changes were observed both in
he overall population and in each ACS subgroup. Some of
he changes in mean LDL-C levels over time were statis-
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Figure 1 Mean Serum LDL-C, HDL-C,
and TC Levels on Days 1, 2, and 4
ACS  acute coronary syndromes; HDL-C  high-density lipoprotein choles-
terol; LDL-C  low-density lipoprotein cholesterol; STEMI  ST-segment eleva-
tion myocardial infarction; TC  total cholesterol; UA  unstable angina.
Mean Lipid Values at Each Time Point
Table 2 Mean Lipid Values at Each Time Po
Lipid Parameter Day 1
LDL-C (n  507) 136.2 (29.9) 1
TC (n  507) 199.5 (34.2) 19
HDL-C (n  506) 39.1 (10.8)
Fasting TG (n  249) 183.4 (93.8) 1
*Significantly different from Day 4 by Scheffé test. †Significantly diffe
ANOVA  analysis of variance; HDL-C  high-density lipoprotein cholestero
TG  triglycerides.ically significant, but the magnitudes of the mean changes
ere small (Table 2). The LDL-C decreased by only 1.70%
n the day after admission and increased by Day 4 by 5.01%.
he median change between Day 1 and 2 was 2 mg/dl
interquartile range [IQR] 11 to 6 mg/dl), between
ays 2 and 4 was 8 mg/dl (IQR 2 to 17 mg/dl), and
etween Days 1 and 4 was 6 mg/dl (IQR 7 to 18
g/dl). Similar patterns were found for STEMI and non-
TEMI, whereas patients with UA did not have signifi-
ant changes in the first 24 h after admission (0.81%).
imilar changes were observed for total cholesterol, and
maller changes were observed for HDL-C.
G levels. Changes in TG levels were analyzed only in
atients who gave a baseline blood sample in the fasting
tate on hospital admission. For this group (n 249), mean
G levels did not significantly change from Day 1 (183.4
g/dl) to Day 4 (177.3 mg/dl) (Fig. 2). Although the mean
ercent change from Day 1 to Day 4 for the overall group
as 9.8%, the median percent change was only 0.62%.
ffect of admission delay on LDL-C. Cohorts were
efined by the recorded length of time between the onset of
ymptoms and the time of first blood sample on admission
Day 1). Time intervals were defined as 0 to 12 h, 12 to
4 h, 24 to 36 h, and 36 to 48 h. These cohorts contained
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Figure 2 Mean Serum Triglyceride Levels
of Fasting Patients on Days 1, 2, and 4
Abbreviations as in Figure 1.
All Patients
2 Day 4 ANOVA p Value
(30.5) 141.8† (31.7) 0.0001
(35.7) 207.8† (36.9) 0.0001
(10.1) 39.6 (10.0) 0.0002
(82.6) 177.3 (80.1) 0.2131
m Day 1 by Scheffé test. Values are mean (SD), mg/dl.int
Day
33.5*
7.0*†
38.6*
77.3
rent fro
l; LDL-C  low-density lipoprotein cholesterol; TC  total cholesterol;
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April 15, 2008:1440–5 Lipid Levels After ACS9 patients, 164 patients, 146 patients, and 96 patients,
espectively (Fig. 3). Corresponding mean times (symptom
nset to first blood sample) for the cohorts were 7.4 h,
8.9 h, 29.3 h, and 42.6 h. Mean LDL-C values in
dmission samples were similar across cohorts, with slightly
igher values in later cohorts. In the cohorts within 1.5 days
f symptom onset (0- to 12-h cohort, 12- to 24-h cohort,
nd 24- to 36-h cohort), there was a small dip in LDL-C
rom admission (Day 1) to the next in-hospital day (Day 2,
ange 3.1 to 6.0 mg/dl), followed by an increase on Day
. Thus, the dip between Day 1 and Day 2 seemed to be
ssociated with the acute hospital admission after the ACS.
n the 36- to 48-h cohort, the first 2 measurements were
ssentially unchanged (0.3 mg/dl), followed by a small
ncrease on Day 4. Analysis of these cohorts provided no
vidence that there was a decrease in LDL-C related to time
rom onset of the ACS.
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Figure 3 Directly Measured Mean LDL-C Levels
Levels among patients divided into 4 cohorts by time from onset of ACS symp-
toms until hospital admission. Time axis shows mean time from onset of
symptoms to blood sampling. Abbreviations as in Figure 1.
Changes in LDL-C Over Time After Hospitalizatio
Table 3 Changes in LDL-C Over Time After H
Group n Day LDL-C, mg/dl
All ACS 507 1 136.2
2 133.5
4 141.8
STEMI 212 1 136.0
2 133.1
4 142.7
Non-STEMI 176 1 134.3
2 129.4
4 137.6
UA 119 1 139.3
2 140.0
4 146.1Abbreviations as in Tables 1 and 2.iscussion
esults of this analysis suggest that directly measured serum
DL-C after admission for an ACS changes slightly in a
tatistically significant but not a clinically meaningful way
5.01%) from Day 1 to Day 4 (Table 3). Randomization
o statin therapy in this study precluded comparative mea-
urement of serum lipid parameters after discharge from the
ospital. Nevertheless, the data show that there is relatively
ittle change in any of the measured parameters in any
ubgroup (Figs. 2 and 3) during the first 4 days after
dmission for an ACS. This suggests that LDL-C deter-
inations can be calculated reliably from lipid levels on the
rst available fasting blood sample rather than waiting for
ischarge or post-discharge blood samples.
When LDL-C levels were analyzed by cohort on the
asis of delay from onset of ACS symptoms to admission,
ean admission values showed no decrease across time with
ohorts ranging from those admitted shortly after the ACS,
ith a mean time from symptom onset to blood draw of
nly 7.4 h, to those admitted as late as 36 to 48 h after
ymptom onset (Fig. 3). This suggests that the small dip in
DL-C was associated with the day after admission (Day 2
f hospitalization), rather than with the time after onset of
CS symptoms. This observation is similar to the slight
ecrease in LDL-C levels from admission to Day 3 found in
atients hospitalized for a variety of complaints, including
nfectious, respiratory, and gastrointestinal diseases (13).
herefore, the decrease in LDL-C concentration on Day 2
f hospitalization may reflect causes related to hospitaliza-
ion, such as altered oral intake or intravenous hydration. In
ddition, in patients with cardiovascular disease, drugs and
rocedures related to diagnosing or treating ACS are known
o affect one or more serum lipid components (14,15).
Early studies of acute MI reported decreases in TC and
DL-C of up to 50% over the time period observed in this
tudy (11). However, as therapeutic intervention has
volved, the magnitude of acute lipoprotein alterations
etected has apparently declined with time. In 2001, the
ACS
talization for ACS
Mean Change From
Day 1, mg/dl (SD)
Mean Percent Change From
Day 1 (SD)
2.71 (13.83) 1.70% (10.01)
5.58 (19.92) 5.01% (15.00)
2.84 (13.23) 1.82% (9.70)
6.76 (20.25) 5.92% (15.29)
4.91 (14.57) 3.33% (10.50)
3.30 (19.37) 3.23% (14.32)
0.78 (13.16) 0.92% (9.34)
6.82 (19.99) 6.01% (15.35)n for
ospi
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Lipid Levels After ACS April 15, 2008:1440–5IRACL (Myocardial Ischemia Reduction with Aggres-
ive Cholesterol Lowering) trial (1) reported that LDL-C
evels obtained during hospitalization in the placebo arm
ere 12% lower than those obtained 16 weeks after dis-
harge from the hospital for ACS. However, only 1 sample
as reported during hospitalization in MIRACL, preclud-
ng any insight into changes in serum lipids during the early
ost-ACS phase. Several smaller recent studies reporting
rom 1999 to 2003 have also shown changes in lipid levels
fter ACS that were less dramatic than those described in
arlier reports (16–19). A large-scale review of patient records
f admissions for MI found relatively little decrease of LDL-C
etween samples taken 24 h (120 mg/dl) and 24 h (116
g/dl) after admission (7). In addition to reflecting an
arlier era of care for ACS, the decrease in lipid levels
bserved in the earlier studies may also relate to their
etrospective nature and reliance on imputed baseline lipid
evels, the relatively small sample sizes involved in many of
hem, and the use of derived LDL-C levels based on
onfasted blood samples, which have inherently higher TG
evels (and therefore, lower calculated LDL-C levels). The
arger recent LATIN (Lipid Assessment Trial–Italian Net-
ork) study of patients admitted within 12 h of symptom
nset for MI or UA found a mean 7% (UA) to 10% (MI)
ecrease from admission to the next day in direct-measured
DL-C that persisted until discharge (20). Measurements
t 3 months showed that total cholesterol and LDL-C in
I and UA patients returned to levels similar to admission
alues, suggesting that admission values were representative
f true baseline levels. The differences in post-admission
ecrease between LUNAR and LATIN may be related to
ifferences in patient populations, hospital practices, and
reatment patterns in the 2 studies.
A limitation of these data is that although serum lipid
alues varied relatively little during the early phase post-
CS, the immediate pre-event values for these patients
ere not available. It is therefore possible that the values
bserved in this study may be lower than the pre-admission
alues because of a number of factors, including use of
eparin, beta-adrenergic blocking drugs, and other drugs
dministered during the early phase of an ACS. There also
ay be an impact on serum lipids of acute-phase reactants,
ytokines, and free fatty acids, all of which are elevated during
he early phase of an ACS. Nevertheless, the important
bservation in the present study is that patients currently
dmitted to the hospital for an ACS now show relatively
ittle variation in serum lipid values over the days after
dmission. As a consequence, we believe that serum lipids
hould be measured early after admission for an ACS so that
ppropriate doses of lipid-lowering therapy may be selected
nd administered at that time.
In summary, the changes in lipid levels after an ACS seen
n this study are much smaller than those noted in older
tudies. However, they are in keeping with trends in the
ore recent literature that show less change after an ACS.
ur major finding of a small transient decrease on the dayfter admission is consistent with changes attributable to
ospitalization and to treatments typically initiated with
CS.
onclusions
n conclusion, reliable knowledge of serum lipid levels early
fter admission to the hospital for an ACS should facilitate
nitiation of lipid-lowering therapy (most likely involving a
tatin), allow a more rational selection of drug dosage, and
dentify the potential need for adjunctive lipid-altering
herapy. The knowledge that mean serum LDL-C and
ther lipid parameters vary relatively little over the early days
fter admission for an ACS should provide an impetus to
easure lipid parameters early after admission, thus provid-
ng a rational basis for clinical decisions about lipid-
owering therapy.
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